Human papillomavirus (HPV) has been more and more widely emphasized as an important cancerigenic factor. Many researches about HPV and different kinds of tumors have been carryied out. Previous epidemiological evidence suggests that the incidence of anal cancer correlats with high-risk subtypes of HPV infection, HPV detection method standardization and the carryingout of prospetive clinical trials will help to further clarify the natural history of HPV infection region, relationship between HPV infection and the qenesis and development of anal cancer.

Lymphoma is a group of malignancies that affect lymphatic system of the body,and often originates from the abnormal cloned proliferation of B,T or NK cell lineage.It contains mainly two categories:Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).The treatment options consist of chemotherapy,radiotherapy,immunotherapy and radioimmunotherapy,et al.It has been demonstrated that lymphomas are typically radiosensitive tumors and undergo apoptosis readily after radiation therapy(RT).RT produces very high local complete response rate for all lymphoma subtypes.This review will mainly focus on the role of RT in the treatment of aggressive lymphoma,indolent lymphoma,extranodal lymphoma and HL,as well as the application of modem RT techniques.

The elastic-plastic indentation properties of materials with varying ratio of hardness to Young's modulus (H/E) were analyzed with the finite element method. And the indentation stress fields of materials with varying ratio H/E on the surface were studied by the experiment. The results show that the penetration depth, contact radius, plastic pileup and the degree of elastic recovery depend strongly on the ratio H/E. Moreover, graphs were established to describe the relationship between the elastic-plastic indentation parameters and H/E. The established graphs can be used to predict the H/E of materials when compared with experimental data.

Objective To evaluate the efficacy and safety of mesalazine modified-release tablets in the treatment of mild and moderate active ulcerative colitis (UC).Methods This study was a multicenter,single-blinded and randomized controlled study.A total of 251 active UC patients in 18 hospitals were enrolled into this study from November 2010 to January 2012.The subjects were divided into the mesalazine modified-release tablets group (n=123) and the mesalazine enteric-coated tablets group (n=128),three times daily,each of which took mesalazine modified-release tablets or mesalazine enteric coated tablets 800 mg,respectively,and the course of treatment was eight weeks.The difference of UC disease activity index (UC-DAI),UC-DAI at the beginning minus UC-DAI at the final evaluation,was calculated at final evaluation.And this was the primary efficacy parameter.Complete remission rate and effective rate were considered as the secondary efficacy parameter.Adverse drug reactions rates of two groups were calculated and taken as safety evalution.If the lower limit of the 95 ％ confidence interval was more than-0.1 in the difference of the decrease in UC-DAI between the two groups,the non-inferiority of mesalazine modified release tablets to mesalazine enteric-coated tablets was demonstrated.The analysis of covariance model was used for the primary efficacy parameter and the sub-group analysis.And chisquare test was used for the comparison between the two groups in the secondary efficacy parameter and in the adverse drug reactions.Results At the final evaluation,the decrease in UC-DAI of mesalazine modified-release tablets group was 2.84 and that of mesalazine enteric-coated tablets group was 2.56.The reduction degree was 0.27.The lower limit of the 95 ％ confidence interval in the difference of the decrease in UC DAI between the two groups was-0.34,which demonstrated the non-inferiority of mesalazine modified release tablets to mesalazine enteric-coated tablets.The complete remission rates of mesalazine modified release tablets group and mesalazine enteric-coated tablets group were 48.33％ (58/120) and 55.65％ (69/124) and the effective rates were 63.33％ (76/120) and 66.94％ (83/124),and there was no statistically significant difference between the two groups (all P＞ 0.05).At final evaluation,the decrease in UC DAI of mild patients (UC DAI 3 to 5 at enrollment) of mesalazine modified-release tablets group and mesalazine enteric-coated tablets group were 2.16 and 2.05,respectively; the difference of mesalazine modified release tablets group and mesalazine enteric coated tablets group of reduction degree of UC-DAI was 0.11,that of moderate patients (UC-DAI 6 to 8 at enrollment) were 3.49 and 3.03,respectively,the difference of mesalazine modified-release tablets group and mesalazine enteric-coated tablets group of reduction degree of UC DAI was 0.46,and there was no statistically significant difference between the groups (all P＞0.05).The adverse drug reactions rates of mesalazine modified-release tablets group and mesalazine enteric coated tablets group were 6.61％ (8/121) and 10.24％ (13/127),and there was no statistically significant difference between the two groups (P＞ 0.05).No serious adverse drug reactions were found in two groups.Conclusion Mesalazine modified release tablets has good efficacy and high safety in the treatment of mild to moderate active UC.

Objective To evaluate the efficacy and safety of mesalazine modified-release tablets in the maintenance treatment of patients with ulcerative colitis (UC) in remission phase.Methods This study was a multi-center,single-blinded and randomized controlled study.From November 2010 to August 2012,251 patients with UC from 18 hospitals were enrolled.According to the randomization table,all patients were divided into the mesalazine modified-release tablets group (n 126) and the mesalazine enteric-coated tablets group (n=125).The course of treatment were both 48 weeks.The primary efficacy parameter of the two groups including the rate of non-recurrence of bloody stool,and the secondary efficacy parameter including period of non-recurrence of bloody stool,period of non-recurrence of UC,incidence of adverse events and adverse drug reactions were observed.The GENMOD model was applied to calculate 95％ confidence interval (CI) of the rate of non-recurrence of bloody stool of the two groups.If the lower limits was over-10％ of the setting,it indicated that the former was not inferior to the latter.Results In 48 weeks of maintenance treatment,the rate of non-recurrence of bloody stool of themesalazinemodified-release tablets group was 82.99％(95％CI 73.53％ to 92.45％) and 73.30％ (95％ CI 64.04％ to 82.56％) in the mesalazine enteric-coated tablets group,respectively,and the difference between the two groups was 9.69％(95％CI-1.15％ to 20.53％ (＞-10％)) which indicated the mesalazine modified-release tablets group was not inferior to the mesalazine enteric-coated tablets group.There was no significant difference in the period of non recurrence of bloody stool and period of non recurrence of UC between the two groups (both P＞0.05).The incidence of adverse events was 48.78％ (60/123) in the mesalazine modified-release tablets group and 48.00％ (60/125) in the mesalazine enteric-coated tablets group,and the difference was not statistically significant (P=0.902).The incidence of adverse reactions was 16.26 ％ (20/123) in the mesalazine modified release tablets group and 13.60 ％ (17/125) in the mesalazine enteric-coated tablets group.There was no statistically significant difference (P =0.556).Conclusion Mesalazine modified release tablets can help maintain long-term remission in patients with UC,and can be used as a safe and effective alternative medicine in the treatments of UC in remission phase.

Objective To isolate and culture meshenchymal stem cells from murine fetal liver.Methods flMSCs from mouse fetuses were isolated by adhering to plastic surface.Growth kinetics was determined by growth curve.Cell cycle and phenotype were analyzed by FACSan flow cytometry.Differentiation of adhering cells was induced and identified.Results Homogenous fibroblast-like cells were predominated in culture.The counting of flMSCs increased 2 fold after 24 hours and 83.76%?2.88% of flMSCs were in G0/G1 phases.flMSCs were CD44,CD29 positive but negative for the markers of hematopoietic cells such as CD45,CD11b.flMSCs were able to differentiate along adipogenic,chondrogenic and osteogenic pathways even after being passaged several times.ConclusionflMSCs can be isolated by their plastic-attachable property and can expand without losing their multiple differentiation potential in vitro.flMSCs may offer an appropriate cell source for stem cell therapy.

Objective To evaluate the efficacy and safety of rabeprazole sodium injection in the treatment of non-esophageal variceal upper gastrointestinal bleeding in comparison with the positive control,omeprazole.Methods From January 2010 to January 2011,231 patients with non-esophageal variceal upper gastrointestinal bleeding from 20 hospitals were divided into rabeprazole group and omeprazole group in this multicenter,randomized,blind,parallel-group,positive drug controlled clinical trial.Hemostasis rate in 72 hours was the primary endpoint.Hemostasis rate in 120 hours,time to hemostasis,blood transfusion volume and the rate of switching treatments were the secondary endpoint.And safety was also analyzed.Chi square test and Wilcoxon rank sum test were performed for statistical analysis.Results At 72 hours after treatment,the hemostasis rates of rabeprazole group and omeprazole group were 98.20％(109/111)and 98.25％(112/114), respectively, and the difference was not statistically significant (P＞0.05).The 95％ confidence interval (CI) of the rate difference between the two group was-3.50 ％ to 3.40 ％.The result of non-inferiority test indicated that the lower limit of the 95％CI of the rate difference between the two groups was-2.95％ (U=5.652,P＜0.01),and rabeprazole group was not inferior to omeprazole group.At 12 hours after treatment,the hemostatic rates of rabeprazole group and omeprazole group were 63.06％(70/111) and 53.51％(61/114),respectively,and there was no statistically significant difference (P＞0.05).At 120 hours after treatment,the hemostasis rates of rabeprazole group and omeprazole group were 99.10 ％ (110/111) and 98.25 ％ (112 /114),and there was no statistically significant difference (P＞0.05).The median time of hemostasis of two groups was 24 hours.During the treatment,there were two cases and seven cases of rabeprazole group and omeprazole group received blood transfusions,respectively;there were 0.90％ (1/111) and 2.63 ％ (3/114) patients switched to other treatment,and no statistically significant difference was found (P＞0.05).The rates of adverse event of rabeprazole group and omeprazole group were 11.61％ (13/112) and 5.26％ (6/114),respectively.The rates of adverse reaction were 6.25％ (7/112) and 4.39％ (5/114),respectively.The differences in the rates of adverse event and adverse reaction between two groups were not statistically significant(both P＞0.05).Conclusion Rabeprazole sodium injection is an effective and safe drug in the treatment of non-esophageal variceal upper gastrointestinal bleeding.

To measure the levels of X ray radiation emitted from computer video display terminals Accumulative doses of X ray radiation emitted from the surface of terminal screen and radiation protcetive screen were measured by highly sensitive LiF(Mg,Cu,P) thermoluminescent dosimetry The average levels of X ray radiation emitted from the surface of terminal screen and radiation protective screen were 0 93 mR/d and 0 24 mR/d respectively [Conclusion]The low energy and low level X ray radiation emitted from the terminals didn′t exceed the related standards

Objective To study the relationship between EBV infection of classic Hodgkin's lyphoma and expression of p16 protein.Methods EBER-1 and p16 protein expression in 80 cases of CHL were studied with EBER-1 oligonucleotide probe and immunohistochemistry respectively.Results 80 cases of CHL were enrolled in this study,including male 52 cases,28 cases of female,male to female ratio of 1.86 ∶ 1.The positive rate of EBER-1 in female was 39.29％ and in male was 63.46％,which have statistically significant difference (x2 =4.298,P =0.038).The positive rate of EBER-1 in children and the older was significantly higher than that in adult (x2 =20.13,P =0.000).EBER-1 positive expression located in the R-S nuclei which positive expression rate was 55.00％,including mixed cell type (MC) 71.79％,lymphocyte depletion type (LD) 42.85％.lymphocyte predominance (LP) 47.06％ and nodular sclerosis type (NS) 29.41％.MG type was significantly higher than NS ( x2 =8.787,P =0.003 ) ; p16 was noted in thc nucleus and cytoplasm.The total positive expression rate was 45％,and subtype positive rates were 47.05％ (LP),48.71％ ( MC),35.29％ (NS) and 42.85％ (LD).There was a negative correlation between p16 protein and EBER-1 ( r =-0.242,P ＜ 0.05 ).Conclusions CHL may be related to EBV latent infection and it can be considered as potential markers to identify HRS cells in diagnosis.

[Objective]To study the possibility of differentiation of rabbit marrow mesenchymal stem cells(MSCs)into endothelial cells in vitro.[Method]BMSCs of rabbits were obtained by using gradient centrifuge method.The adhesive cells were preserved to passage culture to get pure MSCs.MSCs in the second generation were used.After induction with vascular endothelial growth factor(VEGF),microscopic exarm,cytoimmunofluorescent staining confirmd the trial group cells becomes to endothelial cells.W-P corpuscles which was the symbol of endothelial cells were observed by transmission electron microscope.[Result]The differentiated cells demonstrated the characters of endothelial cells under phase contrast microscopy.The cytoimmunofluore-scent staining showed that the trial group cells were induced to endothelial cells.W-P corpuscles could be seen under transmission electron microscope.[Conclusion]The adult rabbit BMSCs can present features of endothelial cells in certain induction medium,they are ideal donor cells of tissue engineering vascularization.